 NRX Pharmaceuticals Inc NASDAQ: NRXP shares are trading higher by 54.1 at 10.45 after the company announced progress on the worldwide commercial-scale development of ZYESAMI. The company announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI was submitted to the FDA, containing documentation that confirmed Nephron Pharmaceuticals, Inc. is prepared to supply ZYESAMI on a commercial scale. 